All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
#IACH2024
Bookmark this article
To update you on the exciting content presented at the 7th Annual Meeting of the International Academy for Clinical Hematology (IACH), we have collated our social media coverage. Catch up with our posts relating to AML below.
CONGRESS | @TheIACH #IACH2024 | POSTER
— AML Hub (@AML_Hub) September 19, 2024
María Solé Rodríguez, Hospital Juan Ramón Jiménez, shares findings from a retrospective study evaluating safety and efficacy of sorafenib + 5-azacitidine in patients with FLT3m AML who were non-intensive chemotherapy candidates (N=3). There… pic.twitter.com/mNRR9PLbYQ
CONGRESS | @TheIACH #IACH2024 | POSTER
— AML Hub (@AML_Hub) September 20, 2024
Joana Correa de Araujo Koury, Hemope, presents a case report of a patient with FLT3m R/R AML who relapsed during gilteritinib treatment before transplantation. The triple combination therapy of gilteritinib, venetoclax, and azacitidine was… pic.twitter.com/Y7MHoaSzuf
CONGRESS | @TheIACH #IACH2024 | POSTER
— AML Hub (@AML_Hub) September 20, 2024
Moazzam Shahzad, @MoffittNews, presents a retrospective study evaluating the impact of MRD status on post-allo-HSCT outcomes in patients with AML (N=3116). Pre-allo-HSCT MRD positive status independently predicted poor OS and DFS, and higher… pic.twitter.com/woaF4Dd60r
CONGRESS | @TheIACH #IACH2024 | PRESENTATION@AlexaSiddon, @YaleMed, discusses whether we should have two classification systems for AML: WHO-HAEM5 and ICC. They highlight that while there is considerable overlap between them, there are several differences in blast cutoffs and… pic.twitter.com/4i506JKl72
— AML Hub (@AML_Hub) September 20, 2024
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— AML Hub (@AML_Hub) September 20, 2024
Christoph Röllig, @Medizin_TUD, shares insights on risk stratification of older patients with AML, emphasizing that stratifying risk for early death is most important. For intensive treatment in fit patients, risk stratification is… pic.twitter.com/nLRCfFacB4
CONGRESS | @TheIACH #IACH2024 | PRESENTATION@ColemanLindsley, @DanaFarber, discusses the role of MRD testing in treatment decision-making in AML. Given that MRD status does not always predict relapse, Lindsley highlights that MRD is not categorical positive vs negative. A deeper… pic.twitter.com/SudnSiCtZi
— AML Hub (@AML_Hub) September 20, 2024
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— AML Hub (@AML_Hub) September 20, 2024
Lisa Pleyer, @CCSalzburg, shares that harmonization of response criteria in patients with AML, MDS, or CMML receiving HMA-based therapy is feasible. PB-CR could be considered to be included in these criteria.
Follow our live feed for… pic.twitter.com/67Zm4w63Z7
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— AML Hub (@AML_Hub) September 21, 2024
Stéphane De Botton, @GustaveRoussy, shares insights on use of doublets vs triplets in older patients with AML. Given the limited efficacy of VEN monotherapy in R/R AML, HMA + VEN doublets appear promising due to synergistic effect but… pic.twitter.com/e1lXs3tnxV
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— AML Hub (@AML_Hub) September 21, 2024
Aditi Shastri @aditishasMD, @EinsteinMed, discusses which patients with AML and MDS should be transplanted. They highlight the role of improved prognostic models and MRD monitoring in selecting patients for allo-HSCT in first CR.… pic.twitter.com/5LO5BgKSYr
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— AML Hub (@AML_Hub) September 21, 2024
Maximilian Stahl @MaxStahlMD, @DanaFarber, shares insights on TP53m higher risk MDS/AML.
▪️ Allo-SCT is the central treatment, if eligible.
▪️ SoC includes HMA monotherapy for allo-SCT ineligible patients and HMA+VEN for those… pic.twitter.com/fBs1MtvuOr
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— AML Hub (@AML_Hub) September 21, 2024
Gabriel Ghiaur, @HopkinsMedicine, discusses novel mechanisms of drug resistance in AML. They highlight that retinoid gradients contributing to MRD in APL and non-APL AML can be bypassed with FDA approved treatments like arsenic… pic.twitter.com/LviPOttkkb
CONGRESS | @TheIACH #IACH2024 | PRESENTATION@TalhaBadarMD, @MayoCancerCare, provides an overview of maintenance therapy post allo-HCT in AML. They highlight current approaches involving FLT3 inhibitors, IDH inhibitors, and HMA-based therapies or pre-emptive DLI.
— AML Hub (@AML_Hub) September 21, 2024
Follow our live… pic.twitter.com/tBmHqDw0XP
Your opinion matters
15 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox